While all the Supreme nations are racing to come up with a vaccine and medicine for the Coronavirus which so far claimed 10,16,128 lives, a statement from researchers at the University of Pittsburgh School of Medicine came as a ray of hope.
According to a peer-reviewed study published in the medical journal EBioMedicine, the clinical trials being carried on mice showed the immunization produced antibodies capable of fighting off COVID-19, the disease caused by the virus. The published study revealed that the vaccine was delivered via a fingertip-sized patch of microscopic needles. This array is a fingertip-sized patch of 400 tiny needles made out of sugar and the spike protein.
The researchers who have been designing coronavirus vaccines since 2003 repurposed those earlier vaccines to target a specific protein that protrudes from the new version. The new vaccine dubbed as PittCoVacc has reportedly produced a surge of antibodies within a span of two weeks which is actually good progress. The team said they hope to start testing the vaccine candidate on people in clinical trials in the next few weeks.
There are currently more than 200 ongoing clinical trials around the world searching for a cure, treatment or vaccine for the virus.